» Articles » PMID: 20576520

SNAIL Induces Epithelial-to-mesenchymal Transition in a Human Pancreatic Cancer Cell Line (BxPC3) and Promotes Distant Metastasis and Invasiveness in Vivo

Overview
Journal Exp Mol Pathol
Publisher Elsevier
Date 2010 Jun 26
PMID 20576520
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

SNAIL, a potent repressor of E-cadherin expression, plays a key role in inducing epithelial-to-mesenchymal transition (EMT) in epithelial cells. During EMT, epithelial cells lose cell polarity and adhesion, and undergo drastic morphological changes acquiring highly migratory abilities. Although there is increasing evidence that EMT is involved in the progression of some human cancers, its significance in the progression of pancreatic cancer remains elusive. In Panc-1, a well-known human pancreatic cancer cell line in which EMT is triggered by TGF-β1 treatment, SNAIL and vimentin are highly expressed, whereas E-cadherin expression is scant. In contrast, another human pancreatic cancer cell line, BxPC3, in which SNAIL expression is not detected, has high levels of E-cadherin expression and does not undergo EMT upon TGF-β1 treatment. After transfecting the SNAIL gene into BxPC3, however, the cells undergo EMT with remarkable alterations in cell morphology and molecular expression patterns without the addition of any growth factors. Furthermore, in an orthotopic transplantation model using SCID mice, SNAIL-transfected BxPC3 displayed highly metastatic and invasive activities. In the immunohistochemical analysis of the tumor derived from the SNAIL-expressing BxPC3, alterations suggestive of EMT were observed in the invasive tumor front. SNAIL enabled BxPC3 to undergo EMT, endowing it with a highly malignant potential in vivo. These results indicate that SNAIL-mediated EMT may be relevant in the progression of pancreatic cancer, and SNAIL could be a molecular target for a pancreatic cancer intervention.

Citing Articles

The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma.

Katt W, Balkman C, Butler S, Byron M, Carney P, Todd-Donato A Sci Rep. 2025; 15(1):7069.

PMID: 40016294 PMC: 11868584. DOI: 10.1038/s41598-025-90574-3.


Opportunities for targeted therapies: trametinib as a therapeutic approach to canine oral squamous cell carcinomas.

Peralta S, Katt W, Balkman C, Butler S, Carney P, Todd-Donato A Res Sq. 2024; .

PMID: 38746473 PMC: 11092801. DOI: 10.21203/rs.3.rs-4289451/v1.


Epithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies.

Goncharov A, Vashakidze N, Kharaishvili G Biomedicines. 2024; 12(2).

PMID: 38398019 PMC: 10886988. DOI: 10.3390/biomedicines12020418.


Novel Epigenetic Modifiers of Histones Presenting Potent Inhibitory Effects on Adenoid Cystic Carcinoma Stemness and Invasive Properties.

Pina P, Jang Y, Emerick C, Scarini J, Sousa S, Squarize C Int J Mol Sci. 2024; 25(3).

PMID: 38338924 PMC: 10855771. DOI: 10.3390/ijms25031646.


Targeting tumor-intrinsic PD-L1 suppresses the progression and aggressiveness of head and neck cancer by inhibiting GSK3β-dependent Snail degradation.

Ahn C, Oh K, Jin B, Lee W, Kim J, Kim H Cell Oncol (Dordr). 2022; 46(2):267-282.

PMID: 36441378 DOI: 10.1007/s13402-022-00748-8.